Immunic (NASDAQ:IMUX) Research Coverage Started at William Blair

William Blair started coverage on shares of Immunic (NASDAQ:IMUX) in a report issued on Tuesday morning, MarketBeat Ratings reports. The firm issued an outperform rating on the stock. William Blair also issued estimates for Immunic’s FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at $0.96 EPS.

A number of other research firms have also recently commented on IMUX. StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Immunic in a research note on Friday, February 21st. Finally, D. Boral Capital restated a “buy” rating and issued a $17.00 price objective on shares of Immunic in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $12.67.

Immunic Stock Performance

NASDAQ:IMUX opened at $1.24 on Tuesday. The stock has a fifty day moving average of $1.08 and a 200 day moving average of $1.21. The firm has a market capitalization of $111.70 million, a price-to-earnings ratio of -1.01 and a beta of 1.89. Immunic has a 52-week low of $0.92 and a 52-week high of $2.11.

Institutional Trading of Immunic

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares in the last quarter. State Street Corp grew its stake in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares during the last quarter. Jane Street Group LLC increased its position in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares in the last quarter. Virtu Financial LLC bought a new position in Immunic during the 3rd quarter valued at approximately $50,000. Finally, HB Wealth Management LLC purchased a new position in Immunic during the fourth quarter valued at $81,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.